Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus, SARS-CoV-2 test positive
Clinical narrative: Experienced minor itching in chest/lungs during the 8 days but no other symptoms; Got covid symptoms again 8 days after course of Paxlovid finished.; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Got covid symptoms again 8 days after course of Paxlovid finished.) and PRURITUS (Experienced minor itching in chest/lungs during the 8 days but no other symptoms) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 treatment.    Concurrent medical conditions included Blood pressure high. Concomitant products included RAMIPRIL from 01-Jan-2022 to an unknown date for an unknown indication.   On 19-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2022, the patient received dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 16-May-2022, the patient experienced SARS-COV-2 TEST POSITIVE (Got covid symptoms again 8 days after course of Paxlovid finished.). On 16-May-2022 at 9:00 AM, the patient experienced PRURITUS (Experienced minor itching in chest/lungs during the 8 days but no other symptoms). At the time of the report, SARS-COV-2 TEST POSITIVE (Got covid symptoms again 8 days after course of Paxlovid finished.) outcome was unknown and PRURITUS (Experienced minor itching in chest/lungs during the 8 days but no other symptoms) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Treatment medication reported.  Company comment: This spontaneous case concerns a 62-year-old female patient with history of interchange of vaccine products, who experienced the unexpected non-serous AESI, SARS-CoV-2 test positive, 178 days after the third dose of mRNA-1273 vaccine and 13 days after a dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE). The patient had minor itching in chest and lungs and was tested positive. The outcome of the event was reported as unknown. She had recently finished a course of Paxlovid (Nirmatrelvir + Ritonavir). Details of first two doses, clinical course, investigation reports were not provided. 6 months after the Moderna 3rd dose the patient had taken one dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE)  Inappropriate schedule of vaccination. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 62-year-old female patient with history of interchange of vaccine products, who experienced the unexpected non-serous AESI, SARS-CoV-2 test positive, 178 days after the third dose of mRNA-1273 vaccine and 13 days after a dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE). The patient had minor itching in chest and lungs and was tested positive. The outcome of the event was reported as unknown. She had recently finished a course of Paxlovid (Nirmatrelvir + Ritonavir). Details of first two doses, clinical course, investigation reports were not provided. 6 months after the Moderna 3rd dose the patient had taken one dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE)  Inappropriate schedule of vaccination. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.